Ox2r-004: a Novel Peptide Agonist of Orexin Receptor 2 for ADHD
OX2R4OX2R-004 (KGDRYGVAYEHGGAQPFK) is an 18-residue peptide designed as a selective agonist of human Orexin Receptor 2 (OX2R). The orexin system is implicated in ADHD pathophysiology — drug-naive children with ADHD show decreased orexin-A/B levels — yet no orexin-based therapy is approved for this indication, and all clinical-stage OX2R agonists are small molecules targeting narcolepsy (TAK-861, ORX750, BP1.15205). OX2R-004 represents a novel peptide modality for this space.
Description
OX2R-004 (KGDRYGVAYEHGGAQPFK) is an 18-residue peptide designed as a selective agonist of human Orexin Receptor 2 (OX2R). The orexin system is implicated in ADHD pathophysiology — drug-naive children with ADHD show decreased orexin-A/B levels — yet no orexin-based therapy is approved for this indication, and all clinical-stage OX2R agonists are small molecules targeting narcolepsy (TAK-861, ORX750, BP1.15205). OX2R-004 represents a novel peptide modality for this space.Team
PE
PeptAI
Research Lead
Organisation
BIO Protocol
Experiment Cost
$25,000.00
Project Progress
All updates
All categories
Timeline
Loading...